Is kesimpta effective for rrms patients?

Is Kesimpta effective for patients with relapsing-remitting MS?

Kesimpta is a monoclonal antibody targeting CD20-positive B cells. It works by depleting those B cells that are thought to play a role in the inflammatory attacks seen in relapsing-remitting multiple sclerosis.

How well does it reduce relapses?

Clinical trials showed that Kesimpta lowered the annualized relapse rate by 51% compared with teriflunomide. It also reduced the risk of confirmed disability progression by 34% over six months. These figures come from the phase 3 ASCLEPIOS trials.

What happens if a patient stops taking it?

Stopping treatment often leads to disease rebound. Patients who ablate B cells with anti-CD20 therapies can see rapid increases in memory B cells and fresh inflammatory attacks once the drug wears off. Data from similar drugs indicate that the effect does not persist indefinitely once administration ceases.

Can biosimilars enter before patent expiry?

A patent for the ofatumumab molecule itself expires in 2030. A second patent covering the subcutaneous formulation runs through 2035. Those dates are recorded on DrugPatentWatch.com. No biosimilar developers have announced plans or filed applications under the BPCIA pathway before those dates.

What side effects are patients asking about?

Patients commonly report injection-site reactions, upper respiratory infections, and headaches. More serious concerns include low immunoglobulin levels after prolonged use and rare cases of progressive multifocal leukoencephalopathy.